AzTrials
AzTrials

Chronic InsomniaNCT02048878

Hyper-Arousal in Chronic Primary Insomnia

An observational study of Chronic Insomnia, run by University of Chicago at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether individuals with chronic insomnia disorder have a higher degree of physiologic arousal (resulting in their trouble sleeping) than good sleepers. Read more about this study

Who is it for?
Ages 21 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Chronic Insomnia
How many people
28 participants
Where
1 siteUnited States
Study dates
Jan 2014to 20 Dec 2016
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Insomniacs and good sleepers

Who may be able to join

  • Men and women with primary insomnia of at least 3 months in duration
  • ages 21-65 years old
  • BMI <35 kg/m2 to enable microneurography
  • Moderate to severe insomnia based on the Insomnia Severity Index (ISI) questionnaire
  • Pittsburgh Sleep Quality Index (PSQI) > 5
  • Self-reported habitual sleep duration < 6.5 hours
Show all 12Show fewer
  • 21-65 years old men and women with BMI <35 kg/m2
  • No insomnia based on ISI questionnaire
  • Self-reported habitual sleep duration ≥ 6.5 hours but < 9 hours
  • PSQI<5
  • Sleep efficiency on PSG with TRT of 8 hours > 85%
  • No history of mental illness, shift work, circadian rhythm disorders

Who cannot join

  • Sleep disorders other than insomnia as assessed by screening PSG (apnea-hypopnea index or AHI ≥ 10, PLM arousal index ≥ 5)
  • Circadian rhythm sleep disorders
  • Diabetic based on HbA1c ≥ 6.5 %. For those with HbA1c ≥ 6.0 but <6.5%, the non-diabetic condition will be confirmed by 2-h oral glucose tolerance test
  • History of meeting DSM-IVR criteria based on the Mini International Neuropsychiatric Interview version 6.0 for any major psychiatric disorder
  • Unstable or serious medical conditions
  • Current, or use within the past month, of psychoactive (other than stable treatment with antidepressants), hypnotic, stimulant or analgesic medications (except occasional non-narcotic analgesics), beta blockers or alpha blockers
Show all 10Show fewer
  • Shift work or other types of self imposed irregular sleep schedules
  • Habitual smoking
  • Habitual alcohol consumption
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

United States1 site
  • The University of Chicago

    Chicago, Illinois, 60637

Other trials in United States

About this study

Official title: Multi-Level Assessment of Physiologic Hyper-Arousal in Chronic Primary Insomnia: A Case Control Study

The purpose of this study is to determine whether individuals with chronic insomnia disorder have a higher degree of physiologic arousal (resulting in their trouble sleeping) than good sleepers. The primary goal is to perform a rigorous quantitative assessment of physiologic hyper-arousal across two domains (autonomic nervous system and neurophysiology) in patients with chronic primary insomnia as compared to good sleepers matched for sex, age, body mass index (BMI) and race/ethnicity.

Keywords
Insomnia
Medical subject headings
Sleep Initiation and Maintenance Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02048878
Study groupRoleWhat they receive
Insomnia groupAssessment of physiologic hyper-arousal across the two following domains: 1. Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness. 2. Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis.
Matched Control GroupAssessment of physiologic hyper-arousal across the two following domains: 1. Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness. 2. Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sympathetic Baroreflex Sensitivity (BRS) Unit

    Direct recording of sympathetic nervous activity in a nerve of the lower leg using a micro-electrode.

    Measured: 2 months after enrollment

  2. Systolic Arterial Pressure Reactivity

    Increase in blood pressure to stress

    Measured: within 2 months after enrollment

Secondary outcomes (4)
  1. Multiple Sleep Latency Test (MSLT)

    MSLT will be used to objectively quantify tendency to fall asleep (sleep latency).

    Measured: 2 months of enrollment

  2. Heart Rate Variability During Wake and During Sleep

    The balance between sympathetic and parasympathetic nervous control of the heart will be determined by spectral analysis of heart rate variability using continuous electrocardiogram (ECG) recording for 24 hours, including the normal sleep period.

    Measured: 2 months after enrollment

  3. Electroencephalography (EEG) During Wake and Sleep

    The EEG will be measured continuously during sleep and at frequent intervals during wake. The signal will be submitted to power spectral analysis to examine spectral power in frequency bands that are typical of arousal and in frequency bands that are typical of deep sleep.

    Measured: 2 months of enrollment

  4. Noninvasive Beat-to-beat Blood Pressure Monitoring

    Measured: 2 months after enrollment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jan 2014 (estimated)
  2. Study startJan 2014
  3. Primary completion9 Dec 2016
  4. Study completion20 Dec 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
28 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02048878
Sponsor's protocol ID
13-1214
Status last verified
Jan 2020
First submitted
27 Jan 2014
Last updated
18 Jan 2020
Data monitoring committee
No
Individual data sharing
No

Publications

  • Carter JR, Grimaldi D, Fonkoue IT, Medalie L, Mokhlesi B, Cauter EV. Assessment of sympathetic neural activity in chronic insomnia: evidence for elevated cardiovascular risk. Sleep. 2018 Jun 1;41(6):zsy048. doi: 10.1093/sleep/zsy048.

    PubMed 29522186

Questions about this trial

What is this clinical trial studying?

An observational study of Chronic Insomnia, run by University of Chicago at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 18 Jan 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sympathetic Baroreflex Sensitivity (BRS) Unit (time frame: 2 months after enrollment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02048878, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in